Use of
This invention relates to methods of using a Listeria vaccine vector to induce a Th1 immune response in subjects having persistent Th2 immune response profiles.
1. A method of inducing a Th1 immune response in a subject having a parasitic infection, the method comprising the step of administering to said subject a therapeutically effective dose of a Listeria vaccine vector, wherein the Listeria vaccine vector expresses and secretes an antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, wherein said antigen is an infectious disease antigen, and wherein said administering produces a Th1 cell-mediated immune response in said parasite infected subject.
2. The method of claim 1 , wherein said additional polypeptide is a Listeriolysin O (LLO) polypeptide, an ActA polypeptide, or a PEST sequence.
3. The method of claim 1 , wherein said subject is human.
4. The method of claim 1 , wherein said antigen is an HIV antigen, a malaria antigen, or a tuberculosis antigen.
5. The method of claim 4 , wherein said antigen elicits an immune response to HIV-1 gag cytotoxic T lymphocyte or to HIV-1 gag T helper epitopes.
6. The method of claim 1 , wherein said parasite is a helminth, or a protozoan parasite.
7. The method of claim 6 wherein said helminth is Schistosoma mansoni.
8. The method of claim 6 , wherein said protozoan parasite is malaria, leishmania, toxoplasma.
9. The method of claim 1 , further comprising the step of administering a booster vaccination.
10. The method of claim 9 , wherein said booster vaccination comprises a DNA vaccine encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a recombinant polypeptide comprising said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a viral vector encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof or a live recombinant Listeria vaccine vector.
11. The method of claim 1 , wherein said response is a therapeutic immune response or a prophylactic immune response.
12. The method of claim 1 , wherein said response is a cytotoxic T-cell response or a memory T-cell response.
13. The method of claim 1 , wherein said Listeria vaccine vector is a recombinant auxotrophic dal/dat mutant Listeria strain.
14. The method of claim 1 , wherein said immune response is against an infectious disease in said subject.
15. The method of claim 14 , wherein said infectious disease is amebiasis, an HIV infection, a malaria infection, a leishmania infection, a trichuris infection, or a tuberculosis infection.
16. The method of claim 14 , wherein said immune response against said infectious disease results in treatment, suppression, or inhibition of said infectious disease.